Anika Therapeutics
ANIK
166 hedge funds and large institutions have $726M invested in Anika Therapeutics in 2017 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 61 increasing their positions, 49 reducing their positions, and 14 closing their positions.
57% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 14
57% more call options, than puts
Call options by funds: $2.67M | Put options by funds: $1.7M
24% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 49
18% more capital invested
Capital invested by funds: $613M → $726M (+$113M)
4% more funds holding
Funds holding: 159 → 166 (+7)
0.5% more ownership
Funds ownership: 84.42% → 84.91% (+0.5%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Kayne Anderson Rudnick Investment Management
Los Angeles,
California
|
+$12.2M |
| 2 |
Goldman Sachs
New York
|
+$6.69M |
| 3 |
Bank of New York Mellon
New York
|
+$2.66M |
| 4 |
SEI Investments
Oaks,
Pennsylvania
|
+$2.3M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$2.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSW
Thompson Siegel & Walmsley
Richmond,
Virginia
|
-$10.2M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$7.62M |
| 3 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
-$5.22M |
| 4 |
Two Sigma Investments
New York
|
-$2.97M |
| 5 |
Nordea Investment Management
Stockholm,
Sweden
|
-$2.25M |
ANIK Hedge Fund Activity: Q3 2017 in Review
166 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q3 2017, worth a combined $726M — up 18% from $613M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new ANIK positions and 14 closed out — a net gain of 8 holders — while 61 added to existing stakes and 49 trimmed.
The largest buyer was Kayne Anderson Rudnick Investment Management, adding an estimated $12.2M. The largest seller was Thompson Siegel & Walmsley, cutting an estimated $10.2M.
- 166 institutional investors held Anika Therapeutics (ANIK) as of Q3 2017, up from 159 in Q2 2017.
- Funds reported $726M of Anika Therapeutics stock for Q3 2017, up 18% quarter-over-quarter.
- 22 funds opened new Anika Therapeutics positions in Q3 2017 and 14 closed out, a net change of +8 holders.
- The largest Anika Therapeutics buyer in Q3 2017 was Kayne Anderson Rudnick Investment Management, an estimated $12.2M added.
- The largest Anika Therapeutics seller in Q3 2017 was Thompson Siegel & Walmsley, an estimated $10.2M sold.
Based on aggregated 13F filings for Q3 2017.